SymbolCLDI
NameCALIDI BIOTHERAPEUTICS, INC.
SectorUNDEFINED
RegionUNDEFINED
IndustryBiological Products, (No Diagnostic Substances)
Address4475 EXECUTIVE DRIVE, SAN DIEGO, CA 92121
Telephone858-794-9600
Fax
Email
Website
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001855485
Description

None

2026-08-19 23:00

Director Peoples George 🟢 acquired 4.0K shares (1 derivative) of Calidi Biotherapeutics, Inc. (CLDI) at $1.36 Transaction Date: Aug 17, 2026 | Filing ID: 039292

Read more
2026-08-19 23:00

Director Leftwich Scott 🟢 acquired 4.0K shares (1 derivative) of Calidi Biotherapeutics, Inc. (CLDI) at $1.36 Transaction Date: Aug 17, 2026 | Filing ID: 039290

Read more
2026-08-19 23:00

Director Stewart Alan R. 🟢 acquired 4.0K shares (1 derivative) of Calidi Biotherapeutics, Inc. (CLDI) at $1.36 Transaction Date: Aug 17, 2026 | Filing ID: 039291

Read more
2026-08-19 23:00

Jackson Andrew C. 🟢 acquired 14.0K shares (1 derivative) of Calidi Biotherapeutics, Inc. (CLDI) at $1.36 Transaction Date: Aug 17, 2026 | Filing ID: 039289

Read more
2026-08-19 23:00

Director Schoeneck James A 🟢 acquired 5.0K shares (1 derivative) of Calidi Biotherapeutics, Inc. (CLDI) at $1.36 Transaction Date: Aug 17, 2026 | Filing ID: 039288

Read more
2026-08-19 23:00

Poma Eric E 🟢 acquired 32.0K shares (1 derivative) of Calidi Biotherapeutics, Inc. (CLDI) at $1.36 Transaction Date: Aug 17, 2026 | Filing ID: 039287

Read more
2026-08-19 23:00

Director Sanders Corazon (Corsee) D. 🟢 acquired 6.0K shares (1 derivative) of Calidi Biotherapeutics, Inc. (CLDI) at $1.36 Transaction Date: Aug 17, 2026 | Filing ID: 039285

Read more
2026-08-14 11:07

New Form SCHEDULE 13G/A - Calidi Biotherapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003562 <b>Size:</b> 10 KB

Read more
2026-08-13 20:45

(30% Negative) CALIDI BIOTHERAPEUTICS, INC. (CLDI) Reports Q3 2026 Financial Results

Read more
2026-08-13 20:30

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Read more